Rare disease biotech company

Drives the growth and market development of the Spark Therapeutics business in the UK, Ireland and Nordic Region. Responsible for establishing Spark’s reputation as the leader in inherited retinal dystrophies and providing commercial leadership in preparation for successful launch and commercialization of SPK-RPE65 and Spark’s pipeline products in Northern Europe.

Rare Diseases UnitGSK’s fledgling Rare Diseases Unit (established 2010) required an experienced orphan disease marketing specialist to drive the commercial development of a flagship portfolio of inherited metabolic disease products.This spanned lysosomal storage disorders (migalastat), amyloidosis (inotersen and dezamizumab) and pulmonary arterial hypertension from pre-clinical to maturity.Led cross functional teams that included market access, commercial analytics, supply chain… Show more Rare Diseases UnitGSK’s fledgling Rare Diseases Unit (established 2010) required an experienced orphan disease marketing specialist to drive the commercial development of a flagship portfolio of inherited metabolic disease products.This spanned lysosomal storage disorders (migalastat), amyloidosis (inotersen and dezamizumab) and pulmonary arterial hypertension from pre-clinical to maturity.Led cross functional teams that included market access, commercial analytics, supply chain, medicine development, medical affairs and accountable for developing and delivering the global product commercial strategy. Show less

Lead and developed EMEA regional marketing strategies in Shire’s flag ship franchise, Fabry Disease, at a particularly turbulent time in the market.

Managed the EU launch of Naglazyme® (galsulfase) for the treatment of MPS VI (approved Jan 2006) and established the European footprint.